Effectiveness of levamisole in rheumatoid arthritis: Immune changes and long-term results.
After a double-blind trial of 4 months, 40 patients with RA were treated with 100 mg Levamisole. Clinical results were good or excellent in 50%. The immunological status is not a valuable criterion for the selection of patients apt to respond to Levamisole. A good correlation was found between clinical improvement, reduction of ESR, percentage of immunoblasts, rheumatoid factor titre and the enhancement of lymphoblastic response to polyclonal mitogens. The treatment maintenance rate for efficacy was much lower for Levamisole than for D-penicillamine.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007978:Levamisole / Q000009:adverse effects / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000627:therapeutic use; D012217:Rheumatoid Factor / Q000032:analysis; D013997:Time Factors
D007136:Immunoglobulins; D007978:Levamisole; D012217:Rheumatoid Factor; D010396:Penicillamine